Colonoscopy Complications: A Medicolegal Review for Attorneys

By Jason Reich, MD — Board-certified in Gastroenterology and Internal Medicine; Gastroenterology Expert Witness and Physician Consultant

Fact-checked September 2026.

Roughly 27 million colonoscopies are projected to be performed in the United States each year over 2026–2035 — about 13 million for screening, 8 million diagnostic, and 6 million surveillance examinations.[1] At that volume, even rare complications occur in absolute numbers: an estimated 8,000 serious bleeding events and 2,000 bowel perforations annually.[2] For attorneys evaluating medical malpractice claims — on either side — colonoscopy complication cases turn less on whether a complication occurred than on what happened next: was it recognized promptly, managed according to accepted practice, and documented. This review covers the three complications that generate the most litigation — perforation, post-polypectomy bleeding, and sedation-related adverse events — the standard of care at each decision point, and the recurring fact patterns that separate an unfortunate outcome from a breach.

The clinical reality: serious complications are rare, and the response is what matters

Per procedure, colonoscopy is remarkably safe. In a population-based screening program, perforation occurred in 0.4 to 0.6 per 1,000 colonoscopies, and post-polypectomy bleeding in 4.3 per 1,000.[3] A prospective multicenter registry found a perforation incidence of 0.66 per 1,000, higher when polypectomy was performed.[4] Diagnostic colonoscopy without intervention is extremely safe; complications arise mostly from polypectomy, particularly with electrocautery.[18]

The gastroenterology quality framework sets explicit targets: fewer than 1 perforation per 500 examinations overall (fewer than 1 per 1,000 for screening colonoscopies), post-polypectomy bleeding under 1%, and at least 90% of post-polypectomy bleeding managed without surgery.[6] These are population-level quality targets, not the standard of care for an individual case — but in litigation they are discoverable, and they frame the expert's analysis of whether the care was acceptable.

The central medicolegal principle of this entire area: perforation and bleeding are known, disclosed risks of colonoscopy. Their occurrence alone does not establish negligence. What I evaluate is the full arc — informed consent, technique, recognition, timeliness of the response, and documentation.

1. Perforation: was it recognized and managed promptly?

Perforation is the complication I encounter most often in high-stakes litigation, because delayed recognition converts a manageable event into peritonitis, sepsis, and death. The risk is not evenly distributed: it rises when polypectomy is performed during the procedure, with advancing age, with comorbidity, and with lower endoscopist procedure volume.[3] In one large Medicare cohort, perforation was associated with a ninefold increase in the odds of death.[5]

• Recognition. The standard is a high index of suspicion. Guidelines direct that perforation be suspected and investigated in any patient who develops abdominal pain, tenderness, distension, fever, or rectal bleeding after colonoscopy — and that CT is the most accurate imaging test to confirm it.[7] The classic failure pattern: the patient reports severe or worsening abdominal pain after discharge, is reassured that it is "just gas" from insufflation, and returns hours or days later with peritonitis. Delayed recognition is an independent predictor of poor outcomes — in the prospective registry it was associated with markedly higher odds of prolonged hospitalization.[4]
• Management. When a perforation is recognized during the procedure, guidelines are clear: endoscopic closure should be attempted — with through-the-scope clips, over-the-scope clips, or suturing — and in more than 90% of such cases closure is effective and surgery is avoided.[8] For perforations recognized after the procedure, management depends on the patient's condition: selected stable patients without signs of sepsis can be managed conservatively with bowel rest, broad-spectrum antibiotics, IV hydration, and close observation — but early improvement does not rule out later deterioration, so monitoring must be close.[7] When surgery is required, it should ideally occur within 24 hours; further delay worsens prognosis.[7] Laparoscopy is the preferred first-line surgical approach.[7]
• Post-polypectomy coagulation syndrome: the critical differential. Not every post-polypectomy abdomen is a perforation. Transmural burn from electrocautery can produce post-polypectomy coagulation syndrome — abdominal pain, fever, and leukocytosis beginning 1 to 5 days after the procedure, without free air on CT — occurring in roughly 1% of electrocautery polypectomies and managed conservatively with an excellent prognosis.[17][18] The medicolegal trap runs both ways: operating unnecessarily on coagulation syndrome, or dismissing a true perforation as "just coagulation syndrome" while sepsis develops. CT findings — specifically the presence or absence of extraluminal air — are what separate the two.[7][17]

2. Post-polypectomy bleeding: was the bleeding risk anticipated and managed?

Bleeding is the most common complication of polypectomy. Immediate bleeding occurs in roughly 2.8% of polypectomies; delayed bleeding — typically presenting within days of the procedure — in 0.2% to 2.2%.[9] Even cold snare polypectomy, often described as low-risk, carries a small but real delayed-bleeding risk of about 0.24%, presenting on average a day and a half after the procedure.[11]

• Risk stratification. The dominant risk factor is polyp size: lesions over 10 mm carry roughly 4.5-fold greater bleeding risk,[13] with the odds of delayed bleeding more than four times higher than for smaller polyps.[10] Right-colon location, immediate bleeding at the time of resection, and endoscopic mucosal resection of large lesions further raise risk — in one retrospective study of lesions 2 cm or larger, delayed hemorrhage occurred in 9.7% of unclipped resection sites versus 1.8% when the defect was fully closed with clips.[19]
• Antithrombotic management. This is where I see the most preventable harm. Heparin bridging around polypectomy has been associated with post-polypectomy bleeding rates as high as 20%, compared with 1.4% without bridging; with temporary interruption and prompt resumption of antithrombotics, overall bleeding rates run 1.8% to 7%, versus up to 11% when agents are continued without interruption.[12] The standard of care is a deliberate periprocedural plan that balances thromboembolic risk against bleeding risk — documented before the procedure, not improvised after the bleed.
• Management of the bleed. Most post-polypectomy bleeding is controlled endoscopically — clip placement, with or without epinephrine injection — and the quality target is that at least 90% be managed without surgery.[6][9] The recurring litigation pattern is not the bleed itself but the response: a patient with delayed bleeding whose calls are not triaged urgently, or who was never given clear discharge instructions about what bleeding warrants an emergency return.

3. Sedation: was the plan appropriate for the patient?

Sedation-related adverse events are uncommon, but they are almost entirely a systems issue — they reflect patient selection, monitoring, and rescue readiness. The ASGE's 2018 guideline on sedation and anesthesia in GI endoscopy, endorsed by the ACG and AGA, sets eight core expectations: assess every patient's sedation risk from pre-existing conditions; use an opioid-plus-benzodiazepine regimen for routine minimal-to-moderate sedation; ensure providers are specifically trained, including rescue from deeper-than-intended sedation; monitor blood pressure, oxygen saturation, and heart rate with clinical observation during every sedated procedure; give supplemental oxygen during deep sedation; consider capnography for deep sedation; consider anesthesia-provider sedation for complex procedures, comorbid patients, or airway risk; and use propofol-based sedation when it is expected to improve safety, comfort, efficiency, or procedure completion.[14]

• How safe is it, in numbers. With propofol, transient hypoxia occurs in 3% to 7% of cases and transient hypotension in 4% to 7%; events requiring assisted ventilation run 0.1% to 0.2%.[15] In a worldwide review of more than 521,000 patients, mask ventilation was needed in 0.1 per 1,000 colonoscopies; there were 4 intubations, 1 neurologic injury, and 3 deaths — all in patients with significant comorbid illness.[15] An ASGE review estimated sedation-related mortality at roughly 8 per 100,000 for endoscopist-directed opioid/benzodiazepine sedation and 0.6 per 100,000 for propofol.[15] A meta-analysis found propofol as safe as traditional sedative agents across GI endoscopy.[16]
• The fact patterns. I look for ASA physical-status assessment — higher ASA class tracks with unplanned cardiopulmonary events[20] — monitoring records showing continuous vitals, and evidence of rescue capability: trained personnel, equipment, and a plan. The cases that warrant scrutiny involve high-risk patients sedated without anesthesia support, gaps in monitoring documentation, or delayed recognition of hypoxia or hypotension.

4. Was informed consent adequate?

Informed consent is both a clinical and a documentation standard: the quality framework targets documented informed consent in more than 98% of procedures.[6] For colonoscopy, adequate consent covers the material risks — perforation, bleeding (including delayed bleeding after polypectomy), and sedation-related cardiopulmonary events — plus the alternatives and the option of declining. In litigation, the consent conversation is reconstructed from the signed form and the procedure note; a generic form with no procedure-specific discussion documented is a vulnerability, particularly when the complication that occurred was never mentioned.

5. What does the documentation show?

As with missed-cancer cases, the record often decides complication litigation. I request and review:

• The signed informed consent and any documented discussion of risks.
• The complete procedure report: indication, technique, polyp size and location, resection method, immediate bleeding and how it was controlled, clip placement, and completeness of examination.
• The sedation record: agents, doses, vital-sign monitoring, ASA classification, and any adverse events with interventions.
• Discharge instructions — specifically what the patient was told about expected versus warning symptoms (abdominal pain, bleeding) and when to seek emergency care.
• All post-procedure communications: phone calls, portal messages, and ED records, with attention to how complaints of pain or bleeding were triaged.
• The endoscopist's and facility's quality data, including perforation and bleeding rates, where available.

A perforation that was recognized immediately, closed endoscopically, and documented thoroughly is a defensible case about a known risk. The same perforation, dismissed over the phone as "gas pain" with no documented triage, is a different case entirely. The medicine is often similar; the timeliness — and the documentation — is what differs.

What expert review actually involves

A credible colonoscopy-complication review reconstructs the entire episode: the indication and consent, the technique and its appropriateness for the lesion, the recognition of the complication, the timeliness and adequacy of the response, and the documentation at every step. It measures each decision against the contemporaneous guidelines and quality benchmarks — not against the outcome. Reviews that treat a known complication as proof of negligence are not expert opinions; they are hindsight, no more valid than reviews that excuse an indefensible delay because "complications happen." The standard is what a reasonably competent gastroenterologist would have done with the information available at the time.

I provide expert review and testimony for both plaintiff and defense counsel in colonoscopy complication matters — perforation, post-polypectomy bleeding, and sedation-related events — as well as in missed colorectal cancer, inflammatory bowel disease, and general gastroenterology standard-of-care cases.

References

1. Modeling study of U.S. colonoscopy volume, reported May 2026. From 2026 to 2035, total annual colonoscopy volume projected at 27 million, including ~13 million screening, ~8 million diagnostic, and ~6 million surveillance examinations. https://www.healio.com/news/gastroenterology/20260505/no-significant-drop-in-colonoscopies-as-noninvasive-crc-test-followups-sustain-demand
2. Editorial: "Too Many Colonoscopies." American Family Physician. October 2025. An estimated 2–3 million low-value colonoscopies per year produce approximately 8,000 serious bleeding events and 2,000 bowel perforations annually. https://www.aafp.org/pubs/afp/issues/2025/1000/editorials-colonoscopies.pdf
3. Paszat LF, Sutradhar R, Luo J, Rabeneck L, Tinmouth J. Perforation and post-polypectomy bleeding complicating colonoscopy in a population-based screening program. Endoscopy International Open. 2021;9(4):E637–E645. Ontario ColonCancerCheck, 2008–2017; 121,626 colonoscopies. Perforation 0.6 per 1,000 (2008–2012) and 0.4 per 1,000 (2013–2017); bleeding 4.3 per 1,000. Risk elevated with age 70–74, comorbidity, polypectomy, and low endoscopist volume. https://doi.org/10.1055/a-1381-7149
4. Lee J, Lee YJ, Seo JW, Kim ES, Kim SK, Jung MK, Heo J, Lee HS, Lee JS, Jang BI, Kim KO, Cho KB, Kim EY, Kim DJ, Chung YJ. Incidence of colonoscopy-related perforation and risk factors for poor outcomes: 3-year results from a prospective, multicenter registry (with videos). Surgical Endoscopy. 2023;37(8):5865–5874. Six tertiary hospitals, 2017–2020; 84,673 colonoscopies, 56 perforations (0.66 per 1,000). Delayed recognition (adjusted OR 187.71) and sigmoid location (adjusted OR 18.57) independent risk factors for prolonged hospitalization. PMID: 37069430. https://pubmed.ncbi.nlm.nih.gov/37069430/
5. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003;95:230–236. SEER-Medicare cohort, 1991–1998: 77 perforations after 39,286 colonoscopies (1.96 per 1,000); perforation associated with adjusted OR 9.0 (95% CI 3.0–27.3) for death. https://www.researchgate.net/publication/10916312_Risk_of_Perforation_After_Colonoscopy_and_Sigmoidoscopy_A_Population-Based_Study
6. ASGE/ACG Task Force on Quality in Endoscopy — quality indicators for colonoscopy (summary review). Targets: informed consent documented >98%; perforation <1/500 all examinations and <1/1,000 screening; post-polypectomy bleeding <1%; bleeding managed without surgery ≥90%. https://ales.amegroups.org/article/view/5368/html
7. de'Angelis N et al. 2017 WSES guidelines for the management of iatrogenic colonoscopy perforation. World J Emerg Surg. 2018. Suspect perforation in post-colonoscopy pain, tenderness, distension, fever, or rectal bleeding; CT is the most accurate imaging; conservative management (bowel rest, broad-spectrum antibiotics, IV hydration, close observation) for stable patients without sepsis; surgery ideally within 24 hours; laparoscopy first-line. http://link.springer.com/article/10.1186/s13017-018-0162-9
8. Pioche M, Bertrand G, Rivory J. Endoscopic perforation during EMR or ESD: who should take care of the patient? (Editorial.) Endoscopy International Open. 2018;6(3):E313–E314. When periprocedural perforation is recognized, endoscopic treatment should be attempted to avoid surgery; in more than 90% of cases endoscopic closure is effective and surgery is avoided. https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0044-101348
9. Review: "Is endoscopic hemostasis safe and effective for delayed post-polypectomy bleeding?" Int J Gastrointest Interv. Immediate post-polypectomy bleeding 2.8%; delayed 0.2–2.2%. Risk factors include hypertension/cardiovascular disease, right-colon location, polyp >10 mm, and resumption of anticoagulation. Most bleeding controlled with clip placement ± epinephrine injection. https://www.ijgii.org/journal/view.html?doi=10.18528/ijgii240067
10. Zhang Q et al. Assessment of risk factors for delayed colonic post-polypectomy hemorrhage: a study of 15,553 polypectomies. PLoS ONE. 2014;9(10):e108290. Delayed bleeding 0.6% of polyps; polyp size >10 mm (OR 4.6) and immediate post-polypectomy bleeding (OR 2.9) significant risk factors. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108290
11. Wen S et al. Risk factors for delayed bleeding after cold snare polypectomy. Int J Colorectal Dis. 2024 (reviewed in ASGE Journal Scan by Rex DK). 26 delayed bleeds among 10,650 cold snare patients (0.24%); presentation on average 1.58 days post-procedure (range 0–5 days). https://www.asge.org/home/resources/publications/journal-scan/issue/risk-factors-for-delayed-bleeding-after-cold-snare-polypectomy
12. Abraham NS. Reducing post-polypectomy bleeding events in patients who require antithrombotic agents. Mayo Clinic. Heparin bridging associated with post-polypectomy bleeding up to 20% vs 1.4% without bridging; with temporary interruption and prompt resumption, overall bleeding 1.8–7%; without interruption, up to 11%. https://www.mayoclinic.org/es/medical-professionals/digestive-diseases/news/reducing-post-polypectomy-bleeding-events-in-patients-who-require-antithrombotic-agents/mac-20479873
13. Ferlitsch M, Hassan C, Bisschops R, et al. Colorectal polypectomy and endoscopic mucosal resection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline — Update 2024. Endoscopy. 2024;56(7):516–545. Polyp size reported as a major risk factor for post-polypectomy bleeding, with polyps >10 mm carrying 4.5-fold greater risk than smaller ones; prophylactic clip closure recommended after EMR of large nonpedunculated colorectal polyps in the right colon. PMID: 38670139. https://www.thieme-connect.com/products/ejournals/html/10.1055/a-2304-3219
14. Early DS, Lightdale JR, Vargo JJ II, et al. Guidelines for sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2018;87(2):327–337. Eight recommendations: pre-procedure risk assessment; opioid + benzodiazepine for routine minimal-to-moderate sedation; specific provider training including rescue; routine BP/oxygen/heart-rate monitoring; supplemental oxygen for deep sedation; capnography considered for deep sedation; anesthesia provider considered for complex/comorbid/airway-risk cases; propofol-based sedation when it improves safety, comfort, efficiency, or completion. https://www.asge.org/home/resources/publications/guidelines/guidelines-for-sedation-and-anesthesia-in-gi-endoscopy
15. SAGES/ASGE review of sedation in endoscopy. Propofol: transient hypoxia 3–7%, transient hypotension 4–7%, assisted ventilation 0.1–0.2%; worldwide 521,000-patient review: mask ventilation 0.1 per 1,000 colonoscopies, 4 intubations, 1 neurologic injury, 3 deaths (all with significant comorbid illness). Sedation-related mortality estimated ~8 per 100,000 (endoscopist-directed opioid/benzodiazepine) vs 0.6 per 100,000 (propofol). https://www.sages.org/wp-content/uploads/2013/04/SAGES_ASGE_Sedation_Endoscopy.pdf
16. Wang D, Chen C, Chen J, Xu Y, Wang L, Zhu Z, et al. The use of propofol as a sedative agent in gastrointestinal endoscopy: a meta-analysis. PLoS ONE. 2013;8(1):e53311. Cardiopulmonary complication incidence with propofol not significantly different from traditional sedative agents. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053311
17. Post-polypectomy syndrome case report and review. PMC. Post-polypectomy (coagulation) syndrome: transmural burn from electrocautery causing localized peritonitis without perforation; presents 1–5 days post-procedure with pain, fever, leukocytosis; incidence ~0.03–1.2% of polypectomies; managed conservatively (bowel rest, fluids, antibiotics) with excellent prognosis. https://pmc.ncbi.nlm.nih.gov/articles/PMC9427180/
18. Anderloni A, Jovani M, Hassan C, Repici A. Advances, problems, and complications of polypectomy (review; Clinical and Experimental Gastroenterology). Diagnostic colonoscopy extremely safe; complications arise mostly from polypectomy with electrocautery. Bleeding most frequent (0.3–2% for diminutive/small polyps; 1–10% for EMR/ESD); perforation second (0–1.5% for EMR); post-polypectomy coagulation syndrome ~1% (only 0.07% require hospitalization). https://pdfs.semanticscholar.org/d616/88d4f3e2e40450dca8b86c9e6c85613e4063.pdf
19. Liaquat H, Rohn E, Rex DK. Prophylactic clip closure reduced the risk of delayed postpolypectomy hemorrhage: experience in 277 clipped large sessile or flat colorectal lesions and 247 control lesions. Gastrointest Endosc. 2013;77(3):401–407. Retrospective report from Indiana University: 524 lesions ≥2 cm in 463 patients; delayed hemorrhage 9.7% in unclipped sites vs 1.8% with complete clip closure; proximal location and polyp size associated with delayed bleeding. https://www.news-medical.net/news/20130320/Special-issue-on-colorectal-cancer-published-in-GIE-Gastrointestinal-Endoscopy-journal.aspx
20. Saltzman JR (on the ASGE sedation/anesthesia guideline). CORI database data: increasing ASA class associated with increased risk of unplanned cardiopulmonary events during endoscopy — underscoring ASA classification for sedation risk stratification. https://www.healio.com/news/gastroenterology/20180221/new-asge-guideline-on-sedation-anesthesia-in-gi-endoscopy-differs-from-asa-on-capnography